Efficient and targeted product development for quality assurance of biological drugs

Purpose and goal:

Antibody-based molecules have enabled new treatments for cancer and infectious diseases and are a strongly growing market. To ensure the quality of these drugs, LC-MS is often used, which requires enzymes in the sample preparation for improved resolution in the analysis. Genovis is a major player in the development of such enzymes, and in this project we have developed a new platform for targeted production of new, effective enzymes to facilitate quality assurance of various biopharmaceuticals.

Expected results and effects:

The new technology platform enables a higher capacity to identify new product candidates and thus meet the market´s growing needs. We therefore see that access to this technology will improve our opportunities to continue to position ourselves as a strong player in the global biopharma market. The project also identified, developed and launched a unique, customer-requested, enzyme for use in analytics for quality assurance of biopharmaceuticals.

Approach and implementation:

The project was carried out in collaboration with Lund University of Technology and Lund University, where the majority of the platform was developed. The interaction between knowledge-driven academia and market- and application-driven industry was very efficient and created good synergy for innovation. The interaction has been very rewarding and further collaboration between the parties will continue.